Mary T Szela - Net Worth and Insider Trading

Mary T Szela Net Worth

The estimated net worth of Mary T Szela is at least $16 Million dollars as of 2024-11-29. Mary T Szela is the Senior Vice President of Abbott Laboratories and owns about 119,422 shares of Abbott Laboratories (ABT) stock worth over $14 Million. Mary T Szela is the CEO AND PRESIDENT of TriSalus Life Sciences Inc and owns about 384,677 shares of TriSalus Life Sciences Inc (TLSI) stock worth over $2 Million. Mary T Szela is also the Director of Coherus BioSciences Inc and owns about 0 shares of Coherus BioSciences Inc (CHRS) stock worth over $0. Details can be seen in Mary T Szela's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Mary T Szela has not made any transactions after 2024-09-13 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Mary T Szela

To

Mary T Szela Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Mary T Szela owns 10 companies in total, including Kura Oncology Inc (KURA) , Coherus BioSciences Inc (CHRS) , and Alimera Sciences Inc (ALIM) among others .

Click here to see the complete history of Mary T Szela’s form 4 insider trades.

Insider Ownership Summary of Mary T Szela

Ticker Comapny Transaction Date Type of Owner
KURA Kura Oncology Inc 2018-11-06 director
CHRS Coherus BioSciences Inc 2020-06-22 director
ALIM Alimera Sciences Inc 2018-06-19 director
LIMIT LIMIT 2017-05-09 director & Chief Executive Officer
LIMIT LIMIT 2016-11-29 director & Chief Executive Officer
LIMIT LIMIT 2011-12-14 Senior Vice President
LIMIT LIMIT 2021-03-11 director
LIMIT LIMIT 2021-07-29 director
LIMIT LIMIT 2024-09-13 director & CEO and President
LIMIT LIMIT 2023-08-10 director & CEO and President

Mary T Szela Latest Holdings Summary

Mary T Szela currently owns a total of 3 stocks. Among these stocks, Mary T Szela owns 119,422 shares of Abbott Laboratories (ABT) as of December 14, 2011, with a value of $14 Million and a weighting of 89.68%. Mary T Szela owns 384,677 shares of TriSalus Life Sciences Inc (TLSI) as of September 13, 2024, with a value of $2 Million and a weighting of 10.32%. Mary T Szela also owns 0 shares of Coherus BioSciences Inc (CHRS) as of June 22, 2020, with a value of $0 and a weighting of 0%.

Latest Holdings of Mary T Szela

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ABT Abbott Laboratories 2011-12-14 119,422 118.95 14,205,247
TLSI TriSalus Life Sciences Inc 2024-09-13 384,677 4.25 1,634,877
CHRS Coherus BioSciences Inc 2020-06-22 0 1.26 0

Holding Weightings of Mary T Szela


Mary T Szela Form 4 Trading Tracker

According to the SEC Form 4 filings, Mary T Szela has made a total of 0 transactions in Abbott Laboratories (ABT) over the past 5 years. The most-recent trade in Abbott Laboratories is the sale of 53,201 shares on December 14, 2011, which brought Mary T Szela around $3 Million.

According to the SEC Form 4 filings, Mary T Szela has made a total of 2 transactions in TriSalus Life Sciences Inc (TLSI) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in TriSalus Life Sciences Inc is the acquisition of 14,815 shares on September 13, 2024, which cost Mary T Szela around $75,408.

According to the SEC Form 4 filings, Mary T Szela has made a total of 1 transactions in Coherus BioSciences Inc (CHRS) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Coherus BioSciences Inc is the sale of 54,997 shares on June 22, 2020, which brought Mary T Szela around $966,847.

Insider Trading History of Mary T Szela

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Mary T Szela Trading Performance

GuruFocus tracks the stock performance after each of Mary T Szela's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mary T Szela is %. GuruFocus also compares Mary T Szela's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mary T Szela within 3 months outperforms times out of transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Mary T Szela's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Mary T Szela

Average Return

No transaction record over 1 Year.

Outperforming Transactions

No transaction record over 1 Year.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -10.61 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -14.88 LIMIT LIMIT LIMIT LIMIT LIMIT

Mary T Szela Ownership Network

Ownership Network List of Mary T Szela

No Data

Ownership Network Relation of Mary T Szela

Insider Network Chart

Mary T Szela Owned Company Details

What does Kura Oncology Inc do?

Who are the key executives at Kura Oncology Inc?

Mary T Szela is the director of Kura Oncology Inc. Other key executives at Kura Oncology Inc include Chief Operating Officer Kathleen Ford , Chief Legal Officer Teresa Brophy Bair , and Chief Medical Officer Stephen Dale .

Kura Oncology Inc (KURA) Insider Trades Summary

Over the past 18 months, Mary T Szela made no insider transaction in Kura Oncology Inc (KURA). Other recent insider transactions involving Kura Oncology Inc (KURA) include a net sale of 4,668 shares made by Teresa Brophy Bair , a net sale of 2,022 shares made by Kathleen Ford , and a net sale of 91,052 shares made by Troy Edward Wilson .

In summary, during the past 3 months, insiders sold 526 shares of Kura Oncology Inc (KURA) in total and bought 0 shares, with a net sale of 526 shares. During the past 18 months, 112,043 shares of Kura Oncology Inc (KURA) were sold and 50,000 shares were bought by its insiders, resulting in a net sale of 62,043 shares.

Kura Oncology Inc (KURA)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Kura Oncology Inc Insider Transactions

No Available Data

Mary T Szela Mailing Address

Above is the net worth, insider trading, and ownership report for Mary T Szela. You might contact Mary T Szela via mailing address: 10835 Road To The Cure, Suite 205, San Diego Ca 92121.

Discussions on Mary T Szela

No discussions yet.